title: Evaluation of the predictive value of topoisomerase II alpha in patients with breast carcinoma.
abstract: Although the increasing body of knowledge in the field of immunohistochemistry and molecular biology has allowed for better understanding of the biology of breast cancer; nevertheless, a search is still in progress for new factors that would make it possible to preselect patients and employ target therapies. Predictive factors that arouse interest include topoisomerases. The authors evaluated the response to treatment and survival rates depending on expression of topoisomerase II alpha (TOP2A) and other predictive factors, as well as assessed treatment effectiveness employing therapeutic schemes based on anthracycline depending on TOP2A expression. The investigations demonstrated that the response to treatment and survival of patients with TOP2A expression were similar to the response and survival of those with tumours demonstrating the presence of other recognized predictors. The employed adjuvant therapy according to anthracycline therapeutic protocols was markedly more effective in TOP2A-positive patients as compared to the remaining individuals. Thus, TOP2A constituted a predictive factor. The study demonstrated that in adjuvant therapy employed in infiltrating ductal carcinoma of the breast, not only HER2 but also TOP2A determination in cancer cells was of importance; for this reason, routine determinations by immunohistochemistry should be performed, especially when anthracycline treatment is planned.
authors.affiliation: Diagnostic Centre "PATOLOG", Rzeszów.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Hajduk
authors.forename: Wojciech P
authors.initials: WP
authors.lastname: Olszewski
authors.forename: Anetta
authors.initials: A
authors.lastname: Smietana
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D008875:Middle Aged; D000075223:Poly-ADP-Ribose Binding Proteins; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D004250:DNA Topoisomerases, Type II; C000618811:TOP2A protein, human